Kids as young as 6 tested in new Wegovy weight loss trial and there was a troubling side effect

Lunchables, Capri Sun… and a skinny jab?GLP-1 weight loss drugs may soon be coming for first graders, with new research from the makers of Ozempic and Wegovy finding that kids between 6 and 11 lost significant weight on the drug, which protects them from serious obesity-related health problems down the line.But parents may want to think twice about seeking a prescription for junior: In addition to weight loss, they found that semaglutide use in young kids also produced a troubling side effect.AdvertisementNovo Nordisk’s new research found that kids on semaglutide (sold as Wegovy) lost weight but also grew over an inch less than kids who were not on the drug.Doctors say it’s unclear how this will affect their adult height, and that’s one of many questions left unanswered about giving these drugs to kids this young.In the US, obesity is exploding among very young children.One in five US children have it, and GLP-1s are already approved to treat kids as young as 12.Legally, doctors can give GLP-1 scrips off-label to kids aged 8 to 11 in extraordinary circumstances — and data shows docs are writing a jaw-dropping 310 times more scrips for this age group than they were just a few years ago.AdvertisementNow, Novo Nordisk is hoping data from their new clinical trial can pave the way for the drug to be officially approved for kids as young as 6.

With the new evidence, they plan to ask the FDA to approve the drug in kids in this age group in 2027.In the study, kids were given once-weekly semaglutide injections or placebo for two years.Both groups also received counseling for diet and exercise.By a year and a half, 79% of the kids on semaglutide lost enough weight to be in a different BMI category, and 38% lost enough to no longer be classified as obese.AdvertisementAt the two-year mark, those on semaglutide dropped 9.4% in BMI.

Meanwhile, placebo raised BMI 8.4% — a total difference of 17.8%.While almost all participants taking the drug experienced side effects...

Read More 
PaprClips
Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by PaprClips.
Publisher: New York Post

Recent Articles